Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome

Table 4

FSHR polymorphisms versus endocrine parameters in non-PCO patients.

	rs2268361			value
	GG	GA	AA
Case number	21	23	19	—
Age, year	27.05 ± 3.57	26.69 ± 4.76	26.84 ± 2.00	0.95
BMI, kg/m^2	21.98 ± 4.13	24.89 ± 14.51	23.73 ± 4.93	0.64
WHR	0.81 ± 0.05	0.88 ± 0.34	0.81 ± 0.07	0.56
Acne score	1 (0–3)	1 (0–3)	1 (0–4)	0.63
mF-G score	7 (0–22)	5 (0–21)	4 (0–16)	0.55
CHOL, mmol/L	4.52 ± 0.77	4.68 ± 0.62	5.05 ± 0.85	0.18
TG, mmol/L	1.42 ± 1.09	1.22 ± 0.47	1.10 ± 0.35	0.50
HDL-C, mmol/L	1.76 ± 0.73	1.54 ± 0.24	1.54 ± 0.30	0.34
LDL-C, mmol/L	2.43 ± 0.77	2.54 ± 0.53	3.00 ± 0.63	0.06
HOMA-IR	2.66 ± 1.92	1.96 ± 1.94	1.96 ± 0.94	0.36
HOMA-ISI	0.03 ± 0.02	0.04 ± 0.03	0.03 ± 0.03	0.40
HOMA-β%	172.07 ± 121.06	120.98 ± 134.90	113.68 ± 65.57	0.25
FSH, IU/L	6.75 ± 1.91	7.25 ± 2.66	5.82 ± 2.17	0.18
LH, IU/L	13.73 ± 10.21	8.87 ± 6.39	8.29 ± 5.21	0.07
PRL, ng/mL	12.61 ± 5.76	19.79 ± 12.53	13.64 ± 9.45	0.06
E2, ng/L	83.42 ± 77.05	85.15 ± 74.46	84.97 ± 132.92	1.00
TT, nmol/L	2.14 ± 1.07	2.75 ± 0.73	2.26 ± 1.19	0.11
A2, ng/mL	4.08 ± 2.16	5.44 ± 2.39	4.56 ± 1.89	0.33
FT, pg/mL	3.32 ± 2.79	3.85 ± 3.22	3.80 ± 3.14	0.82
DHEA-S, ng/mL	2207.05 ± 1064.78	2523.01 ± 1031.51	1916.65 ± 842.80	0.17
E1, pg/mL	100.18 ± 45.10	101.58 ± 40.50	103.79 ± 31.81	0.99
SHBG, nmol/L	89.91 ± 81.37	83.32 ± 75.70	80.99 ± 58.88	0.93
17-OHP, ng/mL	1.23 ± 1.27	1.26 ± 1.00	0.94 ± 0.41	0.65

No analysis was performed for rs2349415 SNP because the size of genotype pattern TT was too small.
PCO: polycystic ovary; BMI: body mass index; WHR: waist-hip ratio; mF-G score: modified Ferriman-Gallwey score; CHOL: cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; HOMA-IR/HOMA-ISI/HOMA-β%: homeostatic model assessment for insulin resistance/insulin sensitivity/β; FSH: follicle stimulating hormone; LH: luteinizing hormone; PRL: prolactin; E2: estradiol; TT: total testosterone; A2: androstenedione; FT: free testosterone; DHEA-S: dehydroepiandrosterone sulfate; E1: estrone; SHBG: sex hormone binding globulin; 17-OHP: 17-hydroxyprogesterone.